Ixekizumab in the treatment of moderate‐to‐severe plaque psoriasis: Patient adherence, satisfaction, and preferences

Ixekizumab is a humanized monoclonal antibody that exhibits its immunomodulatory effects by binding to interleukin 17A (IL‐17A), a proinflammatory cytokine. It was approved for the treatment of plaque psoriasis by the Food and Drug Administration in 2016. Ixekizumab has demonstrated superiority in c...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Dermatologic therapy 2021-01, Vol.34 (1), p.e14486-n/a
Hauptverfasser:	Azhar, Aaminah, Zaayman, Marcus, Silfvast‐Kaiser, Annika, Kivelevitch, Dario, Menter, Alan, Paek, So Yeon
Format:	Artikel
Sprache:	eng
Schlagworte:	adherence ixekizumab preferences psoriasis satisfaction
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!